Melsmon is a preparation containing a hydrolysate of human placenta, used to address asthenic conditions in peri- and postmenopausal women.

Indications for Use:

• Asthenic Conditions:
  • For peri- and postmenopausal women experiencing symptoms such as decreased attention, reduced performance, excessive excitability, and heightened reactivity.

Contraindications:

• Known hypersensitivity to any components of the drug.
• Disorders of the endocrine glands.
• Arterial hypertension.
• Pregnancy and breastfeeding.
• Use in children.

Side Effects:

1. Allergic Reactions:
   • Rash, pruritus (itching), dermatitis, urticaria (hives).
   • Fever, chills, nausea.
2. Local Reactions:
   • Pain, redness, or a sensation of warmth at the injection site.
3. Other:
   • Pain or tenderness in the mammary glands.

Special Instructions:

1. Medical Supervision:
   • Treatment with Melsmon should be conducted under the supervision of a healthcare professional.
2. Routine Medical Examination:
   • Peri- and postmenopausal women are advised to undergo a medical check-up at least once every six months during treatment.
3. Effect on Driving and Machinery Operation:
   • The drug does not impair the ability to drive vehicles or operate machinery.
4. Consultation Recommended:
   • Prior to starting treatment with Melsmon, consult a healthcare provider to determine the suitability of therapy and establish the correct dosage. Self-medication is strongly discouraged and may lead to adverse effects.

• Injection solution (sterile), in 2 ml ampoules.
•  Intended for intramuscular administration.